Oct 28, 2016
A key hallmark of many of the most exceptional deals that the Locust Walk team have done involves having successfully developed the marketplace in advance of and leading up to a significant corporate milestone. As advisors, we are often able to more rapidly engage...
Oct 25, 2016
Biopharma markets stabilize after major drops in 3Q 2015 and 1Q 2016, with potential momentum to the upside in 4Q 2016 and 2017. IPOs have declined to the lowest level in two years, both in terms of the number of completed offerings and the amount of capital raised....
Oct 24, 2016
On Tuesday, October 25th, IvyFon will host a seminar on Family Office Trends. This event is oriented towards persons in the Family Office industry working primarily for single family offices, Ultra High Net Worth Individuals as well as multi-family offices. They will...
Oct 20, 2016
In the Life Sciences universe, most people think of biopharma and medical devices as two separate businesses — never shall the two paths cross. However, there are many overlaps and best practices that can be applied to both sectors. It is widely accepted that...
Oct 14, 2016
In any transaction process, two of the most important considerations for a company are: 1) where to draw the line as to what is considered confidential information 2) at what point confidential information is shared. The dividing line of what is and isn’t confidential...